Purpose This single‐center retrospective clinical study aimed to evaluate the efficacy and feasibility of chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC). Methods Patients with locally advanced ESCC treated with paclitaxel‐liposome‐based chemoradiotherapy between 2016 and 2019 were retrospectively analyzed. Overall survival (OS) and progression‐free survival (PFS) were evaluated using Kaplan–Meier analysis. Results Thirty‐nine patients with locally advanced ESCC were included in this study. The median follow‐up time was 31.5 months. The median OS time was 38.3 (95% confidence interval [CI]: 32.1–45.1) months, and the 1‐, 2‐, and 3‐year OS rates were 84.6%, 64.1%, and 56.2%, respectively. The median PFS time was 32.1 (95% CI: 25.4–39.0) months, and the 1‐, 2‐, and 3‐year PFS rates were 71.8%, 43.6%, and 43.6%, respectively. The most common Grade IV toxicity was neutropenia (30.8%) followed by lymphopenia (20.5%). There were no cases of Grade III/IV radiation pneumonia, and four patients (10.3%) had Grade III/IV esophagitis. Conclusion Chemoradiotherapy using paclitaxel liposome and cisplatin is a well‐tolerated and effective treatment regimen for locally advanced ESCC.

This retrospective clinical study described the treatment efficacy and safety of stereotactic body radiotherapy (SBRT) for patients of hepatocellular carcinoma (HCC) and liver metastasis tumors. The therapeutic effect and prognosis of patients with liver cancer treated with stereotactic body radiation therapy (SBRT) at the Fudan University Shanghai Cancer Center (Shanghai, China) between July 2011 and December 2020 were retrospectively analyzed. Overall survival (OS), local control (LC) rates and progression-free survival (PFS) were evaluated using Kaplan-Meier analysis and the log-rank test. Local progression was defined as tumor growth after SBRT on dynamic computed tomography follow-up. Treatment-related toxicities were assessed according to the Common Terminology Criteria for Adverse Events version 4. A total of 36 patients with liver cancer were enrolled in the present study. The prescribed dosages (14 Gy in 3 fractions or 16 Gy in 3 fractions) were applied for SBRT treatments. The median follow-up time was 21.4 months. The median OS time was 20.4 [95% confidence interval (CI): 6.6-34.2] months, and the 2-year OS rates for the total population, HCC group and liver metastasis group were 47.5, 73.3 and 34.2%, respectively. The median PFS time was 17.3 (95% CI: 11.8-22.8) months and the 2-year PFS rates for the total population, HCC group and liver metastasis group were 36.3, 44.0 and 31.4%, respectively. The 2-year LC rates for the total population, HCC group and liver metastasis group were 83.4, 85.7 and 81.6%, respectively. The most common grade IV toxicity for the HCC group was liver function impairment (15.4%), followed by thrombocytopenia (7.7%). There were no grade III/IV radiation pneumonia or digestive discomfort. The present study aimed to explore a safe, effective and non-invasive treatment method for liver tumors. At the same time, the innovation of the present study is to find a safe and effective prescription dose of SBRT in the absence of consensus on guidelines.

Purpose This retrospective clinical study expounded the clinical application details of stereotactic radiotherapy for liver cancer established in our center. Method The therapeutic effect and prognosis of liver cancer patients treated with stereotactic body radiation therapy (SBRT) from 2011 to 2019 were analyzed retrospectively. The clinical and radiotherapy data were collected and analyzed. Overall survival (OS), local control (LC) rates and progression-free survival (PFS) were evaluated using Kaplan Meier analysis and log-rank test. Local progression was defined as irradiated tumor growth in dynamic computed tomography follow-up. Treatment-related toxicities were assessed according to the Common Terminology Criteria for Adverse Events version 4.3. Results Thirty-six patients with liver cancer were enrolled in this study. The median follow-up time was 21.4 months. The median OS time was 20.4 (95% confidence interval [CI]:6.6–34.2) months, and the 1- and 2-OS rates were 59.6 and 44.2%, respectively. The median PFS time was 17.3 (95% CI:11.8–22.8) months, and the 1- and 2-year PFS rates were 65.6% and 39.1%, respectively. The 1- and 2-year local control rates were 94.2% and 83.4%, respectively. The most common grade IV toxicity was AST/ALT elevation (5.6%) followed by thrombocytopenia (2.8%). There were no cases of grade III/IV radiation pneumonia and digest discomfort. Conclusion The SBRT technology applied in our center for liver cancer is safe and effective. The prescribed dosage (14Gy × 3 Fractions/16Gy × 3 Fractions) we used was reliable and efficient.